专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20160184353A1 ADMINISTRATION OF A THIOL-BASED CHEMOPROTECTANT COMPOUND 审中-公开
标题翻译：一种基于THIOL的化学化合物的管理
公开(公告)号：US20160184353A1
公开(公告)日：2016-06-30
申请号：US14812782
申请日：2015-07-29
申请人： Oregon Health & Science University , Government of The United States of America, d/b/a The Department of Veterans Affairs
发明人： Edward A. Neuwelt , Leslie Muldoon , Michael A. Pagel
IPC分类号： A61K33/24 , A61K9/00 , A61K33/04
CPC分类号： A61K33/04 , A61K9/0019 , A61K9/08 , A61K31/195 , A61K31/198 , A61K31/282 , A61K31/661 , A61K33/24 , A61K38/063 , Y10S514/922 , A61K2300/00
摘要： A method of administration of a thiol-based chemoprotectant agent including NAC (N-acetylcysteine) and STS (sodium thiosulfate) that markedly affects biodistribution and protects against injury from diagnostic or therapeutic intra-arterial procedures. A method for treating or mitigating the side effects of cytotoxic cancer therapy for tumors located in the head or neck and brain tumors. The thiol-based chemoprotectant agent is administered intra-arterially with rapid and first pass uptake in organs and tissues other than the liver.
摘要翻译：施用包含NAC（N-乙酰半胱氨酸）和STS（硫代硫酸钠）的基于硫醇的化学保护剂的方法，其显着影响生物分布并且防止诊断或治疗性动脉内程序的损伤。用于治疗或减轻细胞毒性癌症治疗对位于头部或颈部和脑部肿瘤中的肿瘤的副作用的方法。基于硫醇的化学保护剂在肝脏以外的器官和组织中以动脉内快速和第一次摄取进行动脉内给药。

2. 发明申请

US20110263522A1 ANTITUMOUR COMPOSITIONS CONTAINING TAXANE DERIVATIVES 审中-公开
标题翻译：含有TAXANE衍生物的抗菌组合物
公开(公告)号：US20110263522A1
公开(公告)日：2011-10-27
申请号：US13173268
申请日：2011-06-30
申请人： Marie-Christine BISSERY
发明人： Marie-Christine BISSERY
IPC分类号： A61K31/704 , A61P35/02 , A61P35/00
CPC分类号： A61K31/4745 , A61K31/335 , A61K31/337 , A61K31/505 , A61K31/525 , A61K31/66 , A61K31/675 , A61K31/7048 , A61K31/7072 , A61K33/24 , A61K38/20 , A61K38/21 , A61K38/50 , A61K45/06 , C07D305/14 , C12Y305/01001 , Y10S514/836 , Y10S514/922 , A61K31/28 , A61K2300/00
摘要： Antitumor combinations comprising a taxane and at least one antibiotic for treating neoplastic diseases are described.
摘要翻译：描述了包含紫杉烷和至少一种用于治疗肿瘤疾病的抗生素的抗肿瘤组合。

3. 发明授权

US07531501B1 Method of treating endothelial injury 失效
标题翻译：治疗内皮损伤的方法
公开(公告)号：US07531501B1
公开(公告)日：2009-05-12
申请号：US09525797
申请日：2000-03-15
申请人： Athanasius A. Anagnostou , George Sigounas
发明人： Athanasius A. Anagnostou , George Sigounas
IPC分类号： A61K38/17 , A61K38/19 , A61K38/22 , C07K14/00
CPC分类号： A61K38/1816 , Y10S514/922
摘要： The use of human erythropoietin (EPO) to prevent or treat endothelial injury due to chemotherapy, radiation therapy, mechanical trauma, or to a disease state which damages the endothelium (such as inflammation, heart disease or cancer) is described. The use of EPO in conjunction with the administration of chemotherapeutic agents is described.
摘要翻译：描述了使用人促红细胞生成素（EPO）来预防或治疗由于化疗，放射治疗，机械创伤或损害内皮（如炎症，心脏病或癌症）的疾病状态引起的内皮损伤。描述了EPO与施用化学治疗剂的联合使用。

4. 发明授权

US07307096B2 Combined agents for treatment of glaucoma 失效
标题翻译：联合治疗青光眼药物
公开(公告)号：US07307096B2
公开(公告)日：2007-12-11
申请号：US10146747
申请日：2002-05-16
申请人： Tomihisa Yokoyama
发明人： Tomihisa Yokoyama
IPC分类号： A61K31/41
CPC分类号： A61K45/06 , A61K31/41 , A61K31/415 , A61K31/44 , A61K31/535 , A61K31/55 , A61K31/557 , Y10S514/913 , Y10S514/922 , A61K31/38 , A61K2300/00
摘要： A pharmaceutical composition for the prophylaxis or treatment of glaucoma which comprises an angiotensin II antagonist and at least one compound selected from an adrenaline receptor blocker, a prostaglandin and a carbonic anhydrase inhibitor; and a method for the prophylaxis or treatment of glaucoma by administering the composition to a patient.
摘要翻译：一种用于预防或治疗青光眼的药物组合物，其包含血管紧张素II拮抗剂和至少一种选自肾上腺素受体阻断剂，前列腺素和碳酸酐酶抑制剂的化合物; 以及通过将该组合物给予患者来预防或治疗青光眼的方法。

5. 发明授权

US07294476B2 Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold 有权
标题翻译：同位素特异性抑制治疗疼痛和减少麻醉阈值
公开(公告)号：US07294476B2
公开(公告)日：2007-11-13
申请号：US11200169
申请日：2005-08-10
申请人： Roger A. Johns , Yuanxiang Tao
发明人： Roger A. Johns , Yuanxiang Tao
IPC分类号： G01N33/567
CPC分类号： A61K31/7076 , A61K31/00 , A61K31/52 , A61K31/538 , A61K45/06 , C12Q1/44 , C12Q1/485 , G01N2500/04 , Y10S514/816 , Y10S514/817 , Y10S514/818 , Y10S514/922
摘要： Several lines of evidence have shown a role for the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling pathway in the development of spinal hyperalgesia. However, the roles of effectors for cGMP are not fully understood in the processing of pain in the spinal cord. cGMP-dependent protein kinase (PKG) Iα but not PKGIβ was localized in the neuronal bodies and processes, and was distributed primarily in the superficial laminae of the spinal cord. Intrathecal administration of an inhibitor of PKGIα, Rp-8-[(4-Chlorophenyl)thio]-cGMPS triethylamine, produces significant antinociception. Moreover, PKGIα protein expression was dramatically increased in the lumbar spinal cord after noxious stimulation. This upregulation of PKGIα expression was completely blocked not only by a neuronal NO synthase inhibitor, and a soluble guanylate cyclase inhibitor, but also by an N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801. Noxious stimulation not only initially activates but also later upregulates PKGIα expression in the superficial laminae via an NMDA-No-cGMP signaling pathway, suggesting that PKGIα plays an important role in the central mechanism of inflammatory hyperalgesia in the spinal cord.
摘要翻译：一些证据表明，一氧化氮（NO）/环鸟嘌呤一磷酸（cGMP）信号通路在脊髓痛觉过敏发展中起作用。然而，在治疗脊髓疼痛方面，cGMP的作用者的作用尚未完全了解。 cGMP依赖性蛋白激酶（PKG），而不是PKGIbeta位于神经元体内和过程中，主要分布于脊髓浅层。 PKGIalpha，Rp-8 - [（4-氯苯基）硫代] -cGMPS三乙胺的抑制剂的鞘内施用产生显着的抗感受伤害。此外，PKGIalpha蛋白表达在有害刺激后在腰脊髓中急剧增加。 PKGIalpha表达的上调不仅被神经元NO合成酶抑制剂和可溶性鸟苷酸环化酶抑制剂，而且被N-甲基-D-天冬氨酸（NMDA）受体拮抗剂MK-801完全阻断。有毒刺激不仅最初激活，而且后来通过NMDA-No-cGMP信号通路上调表达薄层中的PKGIalpha表达，表明PKGα在脊髓炎症性痛觉过敏的中枢机制中起重要作用。

6. 发明申请

US20070232692A1 Method of Treating Cancer Using Dithiocarbamate Derivatives 审中-公开
标题翻译：使用二硫代氨基甲酸酯衍生物治疗癌症的方法
公开(公告)号：US20070232692A1
公开(公告)日：2007-10-04
申请号：US11671823
申请日：2007-02-06
申请人： Thomas Kennedy
发明人： Thomas Kennedy
IPC分类号： A61K31/325
CPC分类号： A61K33/24 , A61K31/27 , A61K31/325 , A61K33/04 , A61K33/245 , A61K33/26 , A61K33/30 , A61K33/32 , A61K33/34 , A61K33/36 , A61K33/38 , A61K45/06 , Y10S514/825 , Y10S514/826 , Y10S514/922 , A61K2300/00
摘要： Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions thereof, strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
摘要翻译：二硫代氨基甲酸盐，特别是二硫化四乙基秋兰姆和其硫代氨基甲酸盐阴离子，强烈地抑制各种细胞类型的癌细胞的生长。这种抑制作用由重金属离子如铜离子，细胞因子和血浆铜蓝蛋白增强。提出了使用二硫化四乙基秋兰姆来减少肿瘤生长并增强其他抗癌剂的作用的方法。

7. 发明申请

US20060115533A1 Pharmaceutical compositions 审中-公开
公开(公告)号：US20060115533A1
公开(公告)日：2006-06-01
申请号：US11255359
申请日：2005-10-21
申请人： Patrice Guitard , Barbara Haeberlin , Rainer Link , Friedrich Richter
发明人： Patrice Guitard , Barbara Haeberlin , Rainer Link , Friedrich Richter
IPC分类号： A61K31/724 , A61K31/4745
CPC分类号： A61K31/4745 , A61K9/145 , A61K9/146 , A61K31/436 , A61K31/445 , Y10S514/885 , Y10S514/922 , Y10S514/95 , Y10S514/964 , Y10S514/97
摘要： A pharmaceutical composition in the form of a solid dispersion comprising a macrolide, e.g. a rapamycin or an ascomycin, and a carrier medium.

8. 发明申请

US20050043383A1 Combined agents for treatment of glaucoma 审中-公开
标题翻译：联合治疗青光眼药物
公开(公告)号：US20050043383A1
公开(公告)日：2005-02-24
申请号：US10916052
申请日：2004-08-10
申请人： Tomihisa Yokoyama
发明人： Tomihisa Yokoyama
IPC分类号： A61K45/06 , A61K31/353 , A61K31/382 , A61K31/41 , A61K31/415 , A61K31/437 , A61K31/44 , A61K31/4439 , A61K31/495 , A61K31/535 , A61K31/5377 , A61K31/55 , A61K31/551 , A61K31/557 , A61K31/5575 , A61P27/06 , A61P43/00 , A61K31/4178
CPC分类号： A61K45/06 , A61K31/41 , A61K31/415 , A61K31/44 , A61K31/535 , A61K31/55 , A61K31/557 , Y10S514/913 , Y10S514/922 , A61K31/38 , A61K2300/00
摘要： A pharmaceutical composition for the prophylaxis or treatment of glaucoma which comprises an angiotensin II antagonist and timolol maleate and a method for the prophylaxis or treatment of glaucoma by administering the composition to a patient. The angiotensin II antagonist is of the following formula (I):
摘要翻译：一种用于预防或治疗青光眼的药物组合物，其包含血管紧张素II拮抗剂和马来酸噻吗洛尔酸盐，以及通过将该组合物给予患者来预防或治疗青光眼的方法。血管紧张素II拮抗剂具有下式（I）：

9. 发明申请

US20040157786A1 Antitumor combinations containing taxane derivatives and platinum coordination complexes 审中-公开
标题翻译：含有紫杉烷衍生物和铂配位络合物的抗肿瘤组合
公开(公告)号：US20040157786A1
公开(公告)日：2004-08-12
申请号：US10747207
申请日：2003-12-30
申请人： Aventis Pharma S.A.
发明人： Marie-Christine Bissery
IPC分类号： A61K031/337
CPC分类号： A61K31/4745 , A61K31/335 , A61K31/337 , A61K31/505 , A61K31/525 , A61K31/66 , A61K31/675 , A61K31/7048 , A61K31/7072 , A61K33/24 , A61K38/20 , A61K38/21 , A61K38/50 , A61K45/06 , C07D305/14 , C12Y305/01001 , Y10S514/836 , Y10S514/922 , A61K31/28 , A61K2300/00
摘要： Antitumor combinations comprising a taxane and at least one platinum coordination complex for treating neoplastic diseases are described.
摘要翻译：描述了包含紫杉烷和用于治疗肿瘤疾病的至少一种铂配位复合物的抗肿瘤组合。

10. 发明授权

US06686380B2 Treatment of refractory tumors using epothilone derivatives 有权
$Treatment of refractory tumors using epothilone derivatives$
标题翻译：使用埃坡霉素衍生物治疗难治性肿瘤
公开(公告)号：US06686380B2
公开(公告)日：2004-02-03
申请号：US10072123
申请日：2002-02-08
申请人： Francis Y. F. Lee
发明人： Francis Y. F. Lee
IPC分类号： A61K31425
CPC分类号： A61K31/395 , A61K31/427 , Y10S514/922 , A61K2300/00
摘要： Methods of treating tumors in a mammal, especially a human that has demonstrated resistance to other chemotherapeutic agents, is disclosed. Specifically, methods of the present invention are effective in tumors that have initially been unresponsive to taxane therapy, or have developed resistance during the course of treatment. The methods of the present invention comprise administering epothilone derivatives selected from those represented by the formula: The subject epothilone derivatives are advantageous in addition to their enhanced potency and effectiveness against tumors that have demonstrated resistance to therapy with taxane oncology agents in that they are efficacious upon oral administration.
摘要翻译：公开了治疗哺乳动物，特别是已证明对其它化学治疗剂具有抗性的人的肿瘤的方法。具体而言，本发明的方法在最初对紫杉烷疗法无反应或在治疗过程中产生抗药性的肿瘤中有效。本发明的方法包括施用选自由下式表示的埃坡霉素衍生物：除了它们对抗紫杉烷类肿瘤药物抗药性的肿瘤的效力和效力之外，受试者埃坡霉素衍生物是有利的，因为它们有效口服。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式